Press release
Herpes Labialis Clinical Pipeline |6+ Companies Driving the Next Generation of Treatment Innovations
The Herpes Labialis market is rapidly advancing, fueled by groundbreaking research and innovative therapies from companies such as AiCuris, Heidelberg ImmunoTherapeutics, and Ecogene 21. These industry pioneers are transforming treatment strategies and redefining the future of Herpes Labialis care, bringing new hope to patients worldwide.DelveInsight's 'Herpes Labialis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Herpes Labialis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Herpes Labialis pipeline domain.
For emerging Herpes Labialis drugs, the Herpes Labialis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Herpes Labialis Pipeline Report
• DelveInsight's Herpes Labialis Pipeline analysis depicts a robust space with 6+ active players working to develop 6+ pipeline drugs for Herpes Labialis treatment.
• The leading Herpes Labialis companies include AiCuris, Heidelberg ImmunoTherapeutics, Ecogene 21, Beech Tree Labs, NanoViricides, Maxwell Biosciences., and others are evaluating their lead assets to improve the Herpes Labialis treatment landscape.
• Key Herpes Labialis pipeline therapies in various stages of development include HDIT-101, PRITELIVIR, GSK3943104, mRNA-1608, and others.
• In November 2024, Mustang Bio announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-108, a herpes simplex virus type 1 oncolytic virus and a component of MB-109, for the treatment of malignant glioma. MB-109 combines MB-101, a CAR-T cell therapy targeting interleukin 13 receptor alpha 2, with MB-108, licensed from Nationwide Children's Hospital.
• In October 2024, Mustang Bio received an Orphan Drug Designation from the U.S. FDA for MB-108. This herpes simplex virus type 1 oncolytic virus is also a component of MB-109, developed to treat malignant glioma.
Request a sample and discover the recent breakthroughs happening in the Herpes Labialis pipeline landscape @ https://www.delveinsight.com/report-store/herpes-labialis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Herpes Labialis Overview
Herpes Labialis, commonly known as oral herpes or HSV-1, is a viral infection that affects the mouth area, leading to small, painful blisters on the lips, gums, or throat. These blisters are caused by the herpes simplex virus (HSV-1). The condition is highly prevalent, affecting approximately 67% of adults worldwide. Symptoms typically include painful blisters or ulcers at the site of infection. While cold sores associated with herpes labialis usually resolve within 1-2 weeks, antiviral treatments such as acyclovir and topical creams like docosanol (Abreva) can help alleviate discomfort and speed up healing.
Find out more about Herpes Labialis medication @ https://www.delveinsight.com/report-store/herpes-labialis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Herpes Labialis Treatment Analysis: Drug Profile
HDIT-101: Heidelberg ImmunoTherapeutics
HDIT-101 is a humanized monoclonal antibody developed by Heidelberg ImmunoTherapeutics for the treatment of herpes simplex virus (HSV) infections, including herpes labialis (oral herpes caused by HSV-1). It targets glycoprotein B (gB), a conserved viral protein essential for HSV infectivity and cell-to-cell spread, effectively neutralizing the virus and preventing recurrent outbreaks. HDIT-101 has shown promise in early clinical trials, with Phase I results demonstrating a favorable safety profile, linear pharmacokinetics, and no serious adverse events. Its mechanism of action offers a novel approach, especially for patients with resistance to conventional antiviral therapies.
Currently, HDIT-101 is being evaluated in Phase II trials for both orolabial herpes (MATCH-1 trial) and genital herpes (MATCH-2 trial). The MATCH-1 study focuses on topical application for patients with frequent HSV-1 outbreaks, while the MATCH-2 trial investigates intravenous administration for HSV-2. These trials aim to assess the efficacy of HDIT-101 in reducing outbreak frequency and improving patient outcomes. If successful, HDIT-101 could become a groundbreaking treatment option for managing chronic recurrent herpes infections.
Key Herpes Labialis Therapies and Companies
• HDIT-101: Heidelberg ImmunoTherapeutics
• PRITELIVIR (AIC-316): AiCuris Anti-infective Cures AG
• GSK3943104: GlaxoSmithKline
• mRNA-1608: ModernaTX, Inc.
Learn more about the novel and emerging Herpes Labialis pipeline therapies @ https://www.delveinsight.com/report-store/herpes-labialis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Herpes Labialis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Herpes Labialis Pipeline Report
• Coverage: Global
• Key Herpes Labialis Companies: AiCuris, Heidelberg ImmunoTherapeutics, Ecogene 21, Beech Tree Labs, NanoViricides, Maxwell Biosciences., and others.
• Key Herpes Labialis Pipeline Therapies: HDIT-101, PRITELIVIR, GSK3943104, mRNA-1608, and others.
Dive deep into rich insights for drugs used for Herpes Labialis treatment; visit @ https://www.delveinsight.com/report-store/herpes-labialis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Herpes Labialis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Herpes Labialis Pipeline Therapeutics
6. Herpes Labialis Pipeline: Late-Stage Products (Phase III)
7. Herpes Labialis Pipeline: Late-Stage Products (Phase III)
8. Herpes Labialis Pipeline: Mid-Stage Products (Phase II)
9. Herpes Labialis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Labialis Clinical Pipeline |6+ Companies Driving the Next Generation of Treatment Innovations here
News-ID: 3933679 • Views: …
More Releases from DelveIinsight

Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies …
The Lou Gehrig's Disease market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Denali Therapeutics, AbbVie, Calico Life Sciences, and Clene Nanomedicine Biosciences. These industry pioneers are transforming treatment strategies and redefining the future of Lou Gehrig's Disease, bringing new hope to patients worldwide.
DelveInsight's "Lou Gehrig's Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Lou…

Microbiome Disease Clinical Pipeline | 140+ Companies Advancing Next-Generation …
The microbiome disease market is experiencing rapid growth and is driven by groundbreaking research and cutting-edge therapies. Industry leaders like MaaT Pharma, Qu Biologics, Biomica Ltd., and Seres Therapeutics are pioneering innovative treatment strategies, reshaping the landscape of microbiome-based therapeutics. As these transformative therapies progress through clinical development, they offer new hope for patients worldwide, redefining the future of microbiome disease management.
DelveInsight's 'Microbiome Disease Pipeline Insight 2025' report provides comprehensive…

Metastatic Renal Cell Carcinoma Clinical Pipeline | Over 40 Companies Driving th …
The Metastatic Renal Cell Carcinoma market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like AstraZeneca, Genentech, Sumitomo Dainippon Pharma, and Allogene Therapeutics. These innovators are revolutionizing treatment approaches and shaping the future of Metastatic Renal Cell Carcinoma care, offering new hope for patients worldwide.
DelveInsight's 'Metastatic Renal Cell Carcinoma Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Metastatic Renal Cell Carcinoma therapies in…

Encephalopathy Clinical Pipeline | 70+ Companies Pioneering the Future of Treatm …
The encephalopathy market is advancing rapidly, driven by cutting-edge research and innovative therapies from leading companies such as Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, and Takeda. These pioneers are transforming treatment approaches, reshaping the future of encephalopathy care, and providing new hope for patients worldwide.
DelveInsight's 'Encephalopathy Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Encephalopathy therapies in various stages of clinical development. Major pharmaceutical companies are working…
More Releases for Herpes
Global Herpes Labialis (Oral Herpes) Drugs Market Future Analysis Report 2018-20 …
This report studies the global market size of Herpes Labialis (Oral Herpes) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herpes Labialis (Oral Herpes) Drugs in these regions.
This research report categorizes the global Herpes Labialis (Oral Herpes) Drugs market by players/brands, region, type and application. This report also studies the global market status, competition…
Drugs for Herpes Labialis (Oral Herpes) Market: GSK, Novartis, Teva, Mylan
HTF MI recently broadcasted a new study in its database that highlights the in-depth market analysis with future prospects of Drugs for Herpes Labialis (Oral Herpes) market. The study covers significant data which makes the research document a handy resource for managers, industry executives and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. Some of the…
Global Herpes Labialis (Oral Herpes) Clinical Trials Assessment & Evaluation, H2 …
Market Research Hub (MRH) has include a fresh report to its database titled “Herpes Labialis (Oral Herpes) Global Clinical Trials Review, H2, 2017”, an overview of trial numbers along with the average enrollment in major countries conducted across the globe. Furthermore, the report also presents prominent drugs for in-progress trials based on the count of ongoing trails.
Request Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350157
Oral herpes is a type of infection which occurs on…
Worldwide Herpes Labialis (Oral Herpes) Drugs Information and Market Trend Resea …
Global Herpes Labialis (Oral Herpes) Drugs Market Research Report 2017"" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
Description-
In this report, the global Herpes Labialis (Oral Herpes) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report is segmented…
Global Drugs For Herpes Labialis (Oral Herpes) Market 2017 - Teva, Mylan, Cadila …
Apex Market Reports, recently published a detailed market research study focused on the "Drugs For Herpes Labialis (Oral Herpes) Market" across the global, regional and country level. The report provides 360° analysis of "Drugs For Herpes Labialis (Oral Herpes) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Drugs For…
Drugs for Herpes Labialis (Oral Herpes) Market 2017- Teva, Apotex, Cadila, Mylan …
Apex Research, recently published a detailed market research study focused on the "Drugs for Herpes Labialis (Oral Herpes) Market" across the global, regional and country level. The report provides 360° analysis of "Drugs for Herpes Labialis (Oral Herpes) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Drugs for Herpes Labialis (Oral…